States seek to lower drug prices by targeting the companies that manage them for health plans

The Washington TimesStranački povezanSredinaČinjenice 85Objektivnost 80prije 9 dana

In response to rising concerns about prescription drug affordability, several U.S. states are implementing measures to regulate pharmacy benefit managers (PBMs), which are companies that manage prescription drug benefits for health insurance providers. These efforts include limiting PBMs' compensation, requiring transparency in their operations, and restricting their ownership of retail pharmacies. Tennessee, for example, has passed a law that would prohibit PBMs from operating retail pharmacies starting in 2028, prompting CVS Health to file a federal lawsuit to block the regulation. CVS, along with other major PBMs, argues that they play a critical role in reducing drug costs by negotiating lower prices and increasing the use of generic medications. However, critics contend that the dominance of these companies allows them to exert undue influence over drug pricing. Meanwhile, pharmaceutical companies and PBMs have invested significant resources into advertising campaigns aimed at shaping public perception and resisting regulatory changes.

Procjena pristranosti (Sredina): The article presents both perspectives—critics of PBMs and the companies’ defense—without overtly favoring one side. It includes quotes from both opponents and defenders of PBMs, provides context on legislative actions, and mentions financial investments made by various stakeholders. There is no明显的偏

Zašto ove ocjene (Činjenice 85 · Objektivnost 80): The article accurately reports on state efforts to regulate pharmacy benefit managers and references the KFF poll data about affordability concerns and non-adherence to prescriptions. It aligns closely with the primary source but omits specific details about TrumpRx and partisan differences in perce

ABC News (US)NeovisanSredinaČinjenice 80Objektivnost 75prije 9 dana

States across the U.S. are enacting laws to reduce prescription drug costs by regulating pharmacy benefit managers (PBMs), which oversee prescription coverage for health insurance plans. These companies, including CVS, often own pharmacies and have spent significant resources opposing such regulations. Over 120 bills related to PBMs have been introduced in at least 26 states, with about a quarter passing initial legislative hurdles. Critics argue that PBMs hold too much power in negotiating drug prices, while industry representatives claim they help lower costs through the use of generics. CVS, a major PBM, has faced multiple legal challenges, including a federal court blocking Arkansas' similar legislation and settling lawsuits in Louisiana involving alleged deceptive lobbying practices.

Procjena pristranosti (Sredina): The article presents both perspectives on PBMs: critics highlight their role in driving up drug costs, while industry representatives defend their contributions to cost reduction. The reporting does not clearly favor one side over the other, presenting data on public concern, legislative activity, и

Zašto ove ocjene (Činjenice 80 · Objektivnost 75): This article mirrors the content of item 1, accurately reporting on state-level actions against PBM companies and citing the KFF poll results. It is slightly less detailed than item 1 but still aligns well with the primary source document.

The HillNeovisanKonzervativnoČinjenice 60Objektivnost 65prije 9 dana

Predsjednik Trump je naglasio donošenje Zakona o zaštiti američkih glasača (SAVE America), čiji je cilj rješavanje zabrinutosti o prijevari glasača. Međutim, njegov fokus na ovo pitanje čini se da zasjenjuje šire republikanske prioritete, osobito one povezane s pristupačnošću, koje su ključne za predstojeće izborne izbore.

Procjena pristranosti (Konzervativno): U članku se naglašava Trumpov naglasak na SAVE America Act kao strateški potez koji bi mogao otuđiti birače koji se brinu o pitanjima pristupačnosti.

Zašto ove ocjene (Činjenice 60 · Objektivnost 65): The article discusses the SAVE America Act and Trump's focus on it, but does not mention TrumpRx or the KFF survey findings about public perception of drug costs or government regulation. It lacks specific details from the primary source document, making it only partially factually aligned.